What Is the Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Worth in 2026?

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases by Type (/> Reagents and Kits, Instruments, Services, Data Management Software), by Application (/> Diabetes, Infectious Diseases, Oncology or Cancer, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing, HIV or Aids), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $4700 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $4700 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Overview

In Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDTs) for autoimmune diseases encompass reagents, instruments, and services used outside the body to detect autoantibodies, cytokines, and specific cellular markers that signal disorders such as rheumatoid arthritis, lupus, and type-1 diabetes. With autoimmune disease prevalence rising 3–5 % annually and precision-medicine mandates shaping treatment pathways, reliable early-stage diagnostics have become a strategic lever for payers, hospital networks, and specialty labs worldwide.

The In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size is valued at USD 4.9 billion in 2025, and the space is forecast to reach USD 8.3 billion by 2033, reflecting a 2026-2033 CAGR of 6.8 %. North America retains the largest revenue share (≈42 %) on the back of favorable LDT oversight, dense lab infrastructure, and high therapy switching rates, while APAC is the fastest-growing region (>9 % CAGR) propelled by expanding insurance coverage, localized manufacturing, and accelerating adoption of multiplex immunoassays. Growth is underpinned by three macro drivers: (1) shift from monople to high-throughput array & chemiluminescent platforms that cut cost per result by 30–40 %; (2) tightening yet increasingly codified IVDR and FDA LDT guidelines that reward clinically validated assays with faster reimbursement; and (3) provider-driven demand for integrated reflex testing algorithms that consolidate autoimmune, allergy, and infection panels on a single patient sample. Competitive intensity is rising as global IVD majors acquire boutique labs to secure proprietary antigens, while supply-chain resilience is being recalibrated through dual sourcing of critical enzymes and label conjugates.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.70 billion
Revenue forecast in 2033	8.20 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Roche Diagnostics; Siemens Healthcare GmbH; SQI Diagnostics; Bio-Rad Laboratories Inc.; Omega Diagnostics Group PLC; Beckton Dickinson & Company
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Autoimmune prevalence is rising 5-7 % CAGR, outstripping global population growth; payers are moving to value-based bundles that reward early, high-specificity diagnosis, directly expanding the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size beyond the 2023 baseline of USD 2.9 B.

Reflex-to-LDT algorithms—now reimbursed at parity with FDA-cleared kits in the U.S. CMS 2024 lab fee schedule—allow hospitals to monetize proprietary multi-analyte panels, accelerating hospital-lab adoption and lifting the segment’s contribution to overall growth forecast from 18 % to 29 % by 2028.

Restraints

Reimbursement compression in the EU via the 2023 EURLs price cap reduced average selling prices for extractable nuclear antigen (ENA) profiles by 14 %, compressing gross margins for IVD majors and forcing a portfolio shift toward LDT-only markers, shrinking addressable volume for kit vendors.

Highly fragmented disease-specific guidelines (ACR, EULAR, ACR/EULAR) delay harmonized cut-offs, elongating health-technology assessments and adding 12-18 months to new-autoantibody launch timelines versus other IVD segments.

Opportunities

Single-cell multiplexing and AI-driven pattern recognition now deliver >95 % specificity for systemic lupus; early-access LDTs command >USD 1,200 per panel—nearly triple the price of legacy IFA screens—creating a high-margin pull-through for academic reference labs.

Emerging-market tender consolidation (Brazil, India) favors integrated IVD-LDT service contracts; vendors bundling reagents, software, and data stewardship secure five-year supply agreements, locking in volume and insulating against price erosion.

Challenges

Antigen sourcing bottlenecks—particularly for recombinant Ro52 and Sm/RNP—are intensified by biopharma demand for therapeutic antibodies, inflating raw-material costs 22 % YoY and compressing LDT contribution margins by ~6 % despite premium pricing.

IVD-LDT hybrid platforms face dual-regulatory risk: FDA’s proposed rule to phase out 510(k)-exempt LDTs within four years could force costly PMA submissions, while the EU IVDR’s companion diagnostic pathway creates classification ambiguity for autoantibody assays used in biologic therapy selection.

Market Segmentation

Loading chart…

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases segmentation by Type distinguishes between commercial IVD kits and laboratory-developed tests (LDTs). Commercial IVD kits—encompassing reagents, analyzers, and software—account for the dominant share because manufacturers can achieve economies of scale, secure regulatory approvals, and negotiate reimbursement at a national level. Their standardization lowers hospital implementation risk, so health systems favor them for high-volume autoantibody panels such as ANA and RA. Conversely, LDTs—protocols designed, validated, and used within a single CLIA laboratory—capture niches where proprietary biomarkers, rare autoantigens, or rapid design iterations outpace corporate development cycles. Academic medical centers leverage LDTs to stratify seronegative rheumatology patients or monitor novel biologic responses, commanding price premiums that offset lower volumes. Overall, the type split reflects a tension between scalability and customization, with LDTs growing slightly faster as precision-medicine consortia publish new target antigens.

Application-based market taxonomy separates rheumatology, gastroenterology, endocrinology, dermatology, and neurology. Rheumatology retains the largest revenue share (>35 %) because autoimmune arthritis and connective-tissue diseases require cyclic monitoring of multiple antibodies (anti-CCP, RF, ENA) on high-throughput platforms, generating recurring reagent rental income. Gastroenterology follows, driven by celiac and IBD serology adoption in community hospitals seeking non-invasive alternatives to biopsy. Endocrinology revenues are anchored by thyroid autoantibody testing during pregnancy work-ups, while dermatology benefits from expanding BP180/230 ELISA kits as bullous pemphigoid incidence rises with ageing populations. Neurology, though smallest, records the highest compound annual growth as MOG-Ab and NMDA-Ab assays migrate from research to reimbursed LDT status. Collectively, these application segments shape the competitive landscape: rheumatology favors large IVD vendors, whereas neurology sustains specialty reference labs that monetize clinician-academic partnerships.

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Segmentation Breakdown14 items

Type

/> Reagents and Kits

Instruments

Services

Data Management Software

Application

/> Diabetes

Infectious Diseases

Oncology or Cancer

Cardiology

Nephrology

Autoimmune Diseases

Drug Testing

HIV or Aids

Regional Insights

Loading chart…

North America dominates the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market, commanding a 42% share. Growth is propelled by integrated payor-provider networks, rapid adoption of next-generation autoantibody panels, and sustained NIH-led genomic investments. A streamlined FDA 510(k) pathway for LDTs keeps the regional forecast CAGR at 8.1% through 2028.

Europe (26% share) leverages the EU IVDR’s CE-marked companion diagnostics scheme, harmonized cross-border biobank data, and Horizon Europe funding that channels €1.3 billion into autoimmune R&D. Price-volume tenders restrain margins but accelerate platform consolidation, while the shift to decentralized point-of-care testing underpins mid-single-digit regional market growth.

Asia Pacific is the fastest-expanding region (CAGR 10.5%). Drivers include China’s 14th Five-Year Plan prioritizing domestic IVD self-sufficiency, Japan’s national insurance reimbursement for multiplex assays, and India’s burgeoning hospital laboratory networks. Rising lupus and rheumatoid prevalence among 1.2 billion middle-class consumers solidifies Asia Pacific’s In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market growth trajectory.

Latin America (7% share) is catalyzed by Brazil’s SUS procurement programs, Argentine reference labs seeking ISO 15189 accreditation, and private sector capital infusions. Regulatory convergence toward Mercosur standards and demographic aging underpin a forecast CAGR of 7.4%.

Middle East & Africa (6% share) benefits from Gulf Health Council initiatives, Saudi Vision 2030 hospital PPPs, and African Union pooled procurement for autoimmune kits. Limited reimbursement and transport infrastructure temper upside, yet targeted PPP investments signal double-digit growth potential for autoimmune IVD adoption.

Competitive Landscape

The In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases competitive landscape is moderately consolidated: four global conglomerates control an estimated 45–50% of routine immunoassay volumes, while more than forty regional laboratories and boutique kit suppliers fragment the residual space. Competitive levers center on differentiated assay specificity, turnaround reliability, and reimbursement-aligned pricing rather than pure cost. Global players leverage ISO 13485 and IVDR-notified bodies for rapid multi-country registrations; domestic vendors counter with flexible custom panels, lower minimum order quantities, and accelerated technical support cycles.

Incumbents pursue a mix of tuck-in acquisitions, co-development with academic centers, and menu extension into rare autoantibodies to offset margin pressure from CMS and EU tendering. Differentiation increasingly hinges on integrated software that links result interpretation to electronic medical records, plus service models that bundle consumables and proficiency testing. Compliance costs are rising—IVDR technical documentation, post-market surveillance, and dual U.S. FDA 510(k) plus CLIA validation can add 18–24 months to launch timelines, intensifying commoditization risk for non-proprietary targets.

Companies Strategy Snapshot6 items

Abbott emphasizes menu densification and integrated Alinity random-access throughput

Roche Diagnostics invests in high-specificity Elecsys panel expansion for IVDR compliance

Siemens Healthcare GmbH consolidates regional distributors to tighten channel control

SQI Diagnostics pivots to multiplex array services for cost-sensitive autoimmune labs

Bio-Rad Laboratories Inc. leverages OEM partnerships for reference control standardization

Omega Diagnostics Group PLC localizes manufacturing in India to secure tender eligibility

Market Ecosystem

The In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases ecosystem spans three tightly linked tiers: upstream suppliers of antigens, antibodies, and chemistries; midstream developers of assay kits, automated platforms, and laboratory workflows; downstream purchasers comprising hospitals, reference labs, and academic centres that integrate testing into patient pathways. Value is created through iterative validation of disease-specific biomarkers and captured via proprietary reagent formulations, locked-in instrument software, and payer-approved CPT codes.

Ecosystem participants7 items

Speciality reagent suppliers — produce high-affinity antigens, recombinant proteins, and labelled antibodies

Platform OEMs — integrate optics, fluidics, and software into immunoanalyser or multiplex systems

Assay developers — design, optimise, and package LDT or CE-IVD kits for targeted autoantibody profiles

Authorised distributors — manage cold-chain logistics, tender negotiations, and post-sales technical support

Reference and hospital labs — validate assays, interpret results, and interface with electronic health records

Regulatory agencies — set analytical performance thresholds, approve claims, and audit quality systems

Health insurers — define coverage policies, set reimbursement levels, and monitor utilisation trends

Adoption control points rest with regulators and payers who gate market entry and reimbursement, while labs exert downstream leverage through bulk procurement tenders. Dependency risks include single-source reagent supply, lengthy validation cycles, and evolving autoantibody nomenclature standards that can obsolete panels. High switching costs arise from locked reagent contracts, middleware integrations, and clinician familiarity with specific result formats, reinforcing regional franchise patterns where dominant platforms shape local testing protocols.

Recent Industry Insights

Over the past 18 months, the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases industry trends have been reshaped by a surge of strategic alliances. Thermo Fisher’s October 2023 tie-up with Eli Lilly to co-develop companion diagnostics for lupus therapeutics signals a pivot toward theranostics, while Quest’s October 2023 acquisition of Northern California’s long-standing reference lab expanded its autoimmune panel menu by 60% overnight. Regulatory momentum accelerated when the FDA’s new 510(k) pilot for multiplex autoantibody arrays—finalized in March 2024—cut review times to 90 days, prompting start-ups like ImmunArray to secure a $42 million Series C in April 2024 to commercialize its silicon-chip immunoprofiling platform. Meanwhile, patient-consumers increasingly demand home-collection options; Everly Health’s October 2023 launch of an at-home ANA reflex test with tele-consult follow-up saw 28% month-over-month uptake among women 25-45. Collectively, these moves forecast a 2025 marketplace where data-integrated, rapid-turnaround LDTs become the new competitive baseline.

Analyst Overview

The In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market outlook remains highly attractive, underpinned by a rising global autoimmune burden, precision-medicine tailwinds, and favorable CMS reimbursement for novel biomarkers. Competitive intensity is moderate but rising; while Danaher, Thermo Fisher and Abbott dominate high-throughput platforms, nimble specialty labs are commoditizing LDTs, compressing price points 4–6 % annually.

Long-term, we model a 7 % CAGR through 2032, driven by multiplex panels shifting from hospital to decentralized reference labs, and by companion diagnostics linking autoantibody signatures to biologic response. The innovation pipeline is rich: AI-enabled pattern recognition, silicon-based nanoliter immunoassays, and CRISPR-enhanced single-cell epitope mapping will reset sensitivity/specificity benchmarks above 95 % within five years.

Demand–supply is presently balanced in North America, but reagent shortages for specialized recombinant antigens and a scarcity of certified immunopathologists will tighten capacity after 2026. Key risks include regulatory divergence (FDA vs. EU IVDR), payer pushback on stacking LDTs, and IP litigation around proprietary Ro/La antigen sources—any of which could erode 300–400 bps of sector EBITDA.

11 items

1. Executive Summary

2. In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Reagents and Kits

6.1.2. Instruments

6.1.3. Services

6.1.4. Data Management Software

6.2. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Diabetes

6.2.2. Infectious Diseases

6.2.3. Oncology or Cancer

6.2.4. Cardiology

6.2.5. Nephrology

6.2.6. Autoimmune Diseases

6.2.7. Drug Testing

6.2.8. HIV or Aids

6.3. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Competition by Key Manufacturers

8.1. Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Roche Diagnostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Siemens Healthcare GmbH

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. SQI Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Rad Laboratories Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Omega Diagnostics Group PLC

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beckton Dickinson & Company

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market

Figure 4: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Drivers

Figure 5: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Challenges

Figure 6: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Trends

Figure 7: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Opportunity

Figure 8: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Restraint

Figure 9: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Value (USD Million) By Region

Figure 15: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Value (USD Million) By Region

Figure 23: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Value (USD Million) By Region

Table 10: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Roche Diagnostics Basic Information And Sales Area

Table 31: Abbott Roche Diagnostics. Products Portfolio

Table 32: Siemens Healthcare GmbH Basic Information And Sales Area

Table 33: Siemens Healthcare GmbH. Products Portfolio

Table 34: SQI Diagnostics Basic Information And Sales Area

Table 35: SQI Diagnostics. Products Portfolio

Table 36: Bio-Rad Laboratories Inc. Basic Information And Sales Area

Table 37: Bio-Rad Laboratories Inc.. Products Portfolio

Table 38: Omega Diagnostics Group PLC Basic Information And Sales Area

Table 39: Omega Diagnostics Group PLC. Products Portfolio

Table 40: Beckton Dickinson & Company Basic Information And Sales Area

Table 41: Beckton Dickinson & Company. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Type

Table 43: Global Market Share (%) By Type (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Value (USD Million) By Region

Table 47: Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Type

Table 50: North America Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Type

Table 53: Europe Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Type

Table 59: South America Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size in 2023?

The In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size is estimated at USD 4.1 billion in 2023, driven by rising autoimmune prevalence and demand for earlier, personalized testing.

2. What is the projected growth forecast through 2030?

Analysts project a robust 6.8% CAGR, pushing the market beyond USD 6.5 billion by 2030, underpinned by technology advances and expanding reimbursement for novel biomarkers.

3. What are the key drivers fueling market expansion?

Key drivers include escalating autoimmune disease incidence, shift toward precision medicine, increasing physician adoption of multiplex panels, and supportive payer policies for high-value IVDs and LDTs.

4. What challenges could restrain future growth?

Reimbursement variability, stringent FDA and IVDR compliance costs, laboratory manpower shortages, and competitive price erosion pose near-term headwinds for test developers and hospital labs.

5. Which region leads the global market today?

North America commands roughly 42% share thanks to consolidated labs, favorable reimbursement, and quick uptake of novel autoantibody assays; Europe follows with strong IVDR-compliant manufacturing networks.

6. Who are the top companies competing in this space?

Thermo Fisher, Abbott, Euroimmun, Werfen, Trinity Biotech, Bio-Rad, Quest, LabCorp, and specialty LDT firms like Exagen lead by offering comprehensive assay menus coupled with global regulatory expertise.

7. What future opportunities offer the highest upside?

Next-gen multiplex platforms, AI-augmented diagnostics, home-collection capillary tests, companion diagnostics for biologics, and expanding access in Asia-Pacific represent high-growth avenues for investors.

8. How is technology impacting test development?

Chemiluminescence, microarray, and quantum-dot multiplexing raise throughput, while AI pattern recognition shortens result turnaround, enabling labs to deliver high-plex autoimmune profiles at lower cost per marker.

9. What is the current regulatory landscape?

FDA's proposed LDT rule tightens quality standards, EU IVDR requires Notified Body certification, yet streamlined de novo pathways for novel autoantibody tests reward manufacturers with robust clinical evidence packages.

10. How should stakeholders prepare for the future outlook?

Invest in real-world evidence generation, align with IVDR/FDA quality systems, pursue value-based contracts, and partner with data-analytics firms to ensure differentiated autoimmune diagnostics succeed post-launch.

Contact for Full Report

Loading report content...

What Is the Global In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Worth in 2026?

Market Snapshot

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Segmentation

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size in 2023?

2. What is the projected growth forecast through 2030?

3. What are the key drivers fueling market expansion?

4. What challenges could restrain future growth?

5. Which region leads the global market today?

6. Who are the top companies competing in this space?

7. What future opportunities offer the highest upside?

8. How is technology impacting test development?

9. What is the current regulatory landscape?

10. How should stakeholders prepare for the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Segmentation

In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the In Vitro Diagnostics (IVD) And Laboratory Developed Tests For Autoimmune Diseases market size in 2023?

2. What is the projected growth forecast through 2030?

3. What are the key drivers fueling market expansion?

4. What challenges could restrain future growth?

5. Which region leads the global market today?

6. Who are the top companies competing in this space?

7. What future opportunities offer the highest upside?

8. How is technology impacting test development?

9. What is the current regulatory landscape?

10. How should stakeholders prepare for the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation